Corline's Q3 2024 saw lower revenue but sharply reduced costs as it pivots to a focused strategy supporting key medtech launches and partnerships, aiming for profitability by end-2025. A directed share issue will strengthen liquidity for the transition.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.